Sponsored Ad
Search Results

(±)-Zanubrutinib 5mg  | Purity Not Available

Selleck Chemicals

(±)-Zanubrutinib ((±)-BGB-3111) is the racemate of Zanubrutinib (HY-101474A). (±)-Zanubrutinib inhibits Bruton’s tyrosine kinase (Btk) with an IC50 of 0.63 nM.

More Information Supplier Page

(±)-Zanubrutinib 5 mg  | 98.19%

TargetMol

(±)-Zanubrutinib is a potent and orally available Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher exposure and more complete target inhibi.

More Information Supplier Page

(±)-Zanubrutinib 10 mg  | 98.19%

TargetMol

(±)-Zanubrutinib is a potent and orally available Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher exposure and more complete target inhibi.

More Information Supplier Page

(±)-Zanubrutinib 50 mg  | 98.19%

TargetMol

(±)-Zanubrutinib is a potent and orally available Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher exposure and more complete target inhibi.

More Information Supplier Page

(±)-Zanubrutinib 1 mL  | 98.19%

TargetMol

(±)-Zanubrutinib is a potent and orally available Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher exposure and more complete target inhibi.

More Information Supplier Page

(±)-Zanubrutinib 1 mg  | 98.19%

TargetMol

(±)-Zanubrutinib is a potent and orally available Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher exposure and more complete target inhibi.

More Information Supplier Page

(±)-Zanubrutinib 25 mg  | 98.19%

TargetMol

(±)-Zanubrutinib is a potent and orally available Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher exposure and more complete target inhibi.

More Information Supplier Page

(±)-Zanubrutinib 100 mg  | 98.19%

TargetMol

(±)-Zanubrutinib is a potent and orally available Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher exposure and more complete target inhibi.

More Information Supplier Page

(±)-Zanubrutinib 500 mg  | 98.19%

TargetMol

(±)-Zanubrutinib is a potent and orally available Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher exposure and more complete target inhibi.

More Information Supplier Page